A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease

Crohn's Disease Clinical Trial

Official title:

A Phase 1 Clinical Study to Evaluate the Safety of Allogeneic Adipose-derived Stem Cells in the Subjects With Crohn's Disease

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02580617
• Other study ID #: ALLO-ASC-CD-101
• Status: Recruiting
• Phase: Phase 1
• Start date: November 9, 2015
• Est. completion date: December 2023

Study information

• Verified date: August 2023
• Source: Anterogen Co., Ltd.
• Contact: Won Ho Kim, MD., PhD
• Phone: 82-2-2228-1951
• Email: kimwonho[@]yuhs.ac
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase I study to evaluate the safety of ALLO-ASC-CD for the treatment of crohn' disease. ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells.

Description:

Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore, their immunomodulatory effects are significant for treating immune-related diseases, such as crohn's disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 9
• Est. completion date: December 2023
• Est. primary completion date: December 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 65 Years

Eligibility

Inclusion Criteria:

1. Subject is 18 to 65 years of age

2. Subject who is diagnosed Crohn's disease by endoscopic or radiologic result during more than 6 months

3. Subject who show intolerance or failure of conventional therapy (steroids, immunosuppressive and TNF-alpha inhibitor)

4. Subject who is included CDAI 220-450 during screening period

5. CRP>0.5mg/dL during screening period

6. Subject who show affected sites by crohn's disease in either ileum and large intestine or both of them, including more than 1 nonanastomotic ulcers as a result of colonoscopy.

7. Subjects who satisfy those clinical examination value below during screening period. A. Hemoglobin = 8.0g/dL B. WBC = 3,000/µL C. Lymphocyte = 500/µL D.100,000/µL = Platelet = 1,200,000/µL E. AST and ALT = 3 x the upper limit of normal F. ALP = 3 x the upper limit of normal G.Serum creatinine = the upper limit of normal H.Serum albumin = 2.0g/dL I.PT , aPTT= the upper limit of normal

8. Negative for urine beta-HCG for women of childbearing age.

9. Subject is able to give written informed consent prior to study start and to comply with the study requirements.

Exclusion Criteria:

1. Subject with gastro-intestinal tract A. Crohn's disease which is invaded only proximal ileum. B. The evidence of an intra abdominal abscess during screening period. C. The evidence of an abscess around the anus during screening period. D. Conditions of subtotal colectomy or total colectomy. E. Short bowel syndrome. F. Subject who conduct elemental diet, tube feeding or parenteral nutrition within 3 weeks before enrollment. G. Subject who have ileostomy or colostomy. H Subject who have a bowel stricture of large intestine that may be significant by PI's decision during screening period. I. In case that the PI anticipates that patients need to get a surgical intestinal tract surgery caused by crohn's disease. J. Subject who have adenoma of large intestine K. Subject who have chronic inflammation-associated dysplasia.

2. Subjects who have been received biological therapy within 60 days of enrollment..

3. Subject with infectious disease A. Acute or chronic active HBV, HAV and HIV B. Active tuberculosis. C. IGRA (Interferon-Gamma Release Assay) positive D. All kinds of live vaccine inoculation except influenza vaccine within 4weeks before registration E. Pneumonia, pyelonephritis and Infection of Clostridium within 4weeks during screening visit. F.Subject has history of bacteremia or other serious bacterial or fungal infection in past 3 months.

4. Subject who has malignant tumor or which is not cured yet

5. Subject has any serious disease, in the opinion of the Investigator, would interfere with the evaluation of the study.

6. Subject who has history of blood clots and other pathological arterial thrombosis or venous thrombosis

7. Subject who has a hypersensitive reaction to bovine-derived proteins

8. Subject who is surgery or trauma within 6 weeks before registration

9. Subject who is pregnant or breast-feeding.

10. Subjects who are unwilling to use an "effective" method of contraception during the study

11. Subject who is experienced stem cell therapy

12. Subject who has been enrolled in another clinical study within 4weeks days of screening

13. Subject who has history of alcohol or drug abuse.

14. Subject who is not able to understand the objective of this study or to comply with the study requirements

Related Conditions & MeSH terms

• Crohn Disease
• Crohn's Disease

Intervention

Biological:
• ALLO-ASC
Infusion for Crohn's disease

Locations

Country	Name	City	State
Korea, Republic of	Yonsei University College of Medicine	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Anterogen Co., Ltd.

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety (Clinically measured abnormality of laboratory tests and adverse events)	Clinically measured abnormality of laboratory tests and adverse events	up to 4 weeks
Secondary	CDAI value	Change in the CDAI value	up to 4 weeks
Secondary	The ratio of patients applicable to CDAI <150	The ratio of patients applicable to CDAI <150	Week 4